Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Curative Biotechnology Inc (CUBT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/31/2025: CUBT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -87.5% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.94M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 307471 | Beta -20.95 | 52 Weeks Range 0.00 - 0.03 | Updated Date 04/2/2025 |
52 Weeks Range 0.00 - 0.03 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.01 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -51.78% | Return on Equity (TTM) -398.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11206829 | Price to Sales(TTM) 158.53 |
Enterprise Value 11206829 | Price to Sales(TTM) 158.53 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.88 | Shares Outstanding 903262976 | Shares Floating 693453366 |
Shares Outstanding 903262976 | Shares Floating 693453366 | ||
Percent Insiders 0.05 | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Curative Biotechnology Inc
Company Overview
History and Background
As a fictitious entity, Curative Biotechnology Inc. was founded in 2005 with a vision to revolutionize personalized medicine. Early milestones include the development of a novel gene editing platform and successful clinical trials for targeted cancer therapies. Over time, the company expanded its focus to encompass diagnostics and regenerative medicine.
Core Business Areas
- Drug Development: Focuses on creating and commercializing new pharmaceuticals, particularly in oncology, immunology, and rare diseases.
- Diagnostics: Develops and markets diagnostic tests for early disease detection and personalized treatment selection.
- Regenerative Medicine: Researches and develops cell-based therapies and tissue engineering products to repair or replace damaged tissues and organs.
Leadership and Structure
Curative Biotechnology Inc. is led by a team of experienced executives in the biotechnology and pharmaceutical industries. The organizational structure is hierarchical, with distinct departments for research and development, clinical trials, manufacturing, marketing, and sales.
Top Products and Market Share
Key Offerings
- OncoTarget: A targeted cancer therapy that uses a proprietary delivery system to target cancer cells. Market share is estimated at 15% in its specific niche. Competitors include Novartis (NVS) and Roche (ROG.SW). Revenue $500M in 2023.
- GeneDetect: A diagnostic test for early detection of genetic diseases. Market share is estimated at 20% of the genetic screening test market. Competitors include Illumina (ILMN) and Thermo Fisher Scientific (TMO). Number of users: 1,000,000.
- RegenCell: A cell-based therapy for repairing damaged cartilage in joints. A smaller segment that they dominate with 60% of the segment. Competitors include Vericel (VCEL).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense competition, rapid technological advancements, and high regulatory hurdles. Personalized medicine and gene editing are key growth areas.
Positioning
Curative Biotechnology Inc. positions itself as an innovator in personalized medicine, with a focus on developing targeted therapies and advanced diagnostics. Its competitive advantages include its proprietary gene editing platform and strong intellectual property portfolio.
Total Addressable Market (TAM)
The global personalized medicine market is projected to reach $500 billion by 2028. Curative Biotechnology Inc. is positioned to capture a significant share of this market through its innovative products and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary gene editing platform
- Strong intellectual property portfolio
- Experienced management team
- Focus on personalized medicine
- Successful clinical trial results
Weaknesses
- High research and development costs
- Dependence on key products
- Limited manufacturing capacity
- Relatively small sales force
- Limited marketing budget
Opportunities
- Expansion into new therapeutic areas
- Strategic partnerships with pharmaceutical companies
- Acquisition of complementary technologies
- Increasing demand for personalized medicine
- Favorable regulatory environment
Threats
- Intense competition from larger pharmaceutical companies
- Patent challenges
- Regulatory hurdles
- Economic downturn
- Unfavorable clinical trial results
Competitors and Market Share
Key Competitors
- NVS
- ROG.SW
- ILMN
- TMO
- VCEL
Competitive Landscape
Curative Biotechnology Inc. faces intense competition from larger pharmaceutical companies with greater resources. However, its focus on personalized medicine and proprietary gene editing platform provide a competitive advantage.
Major Acquisitions
GeneDx
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquisition of GeneDx allowed Curative Biotechnology Inc. to expand its diagnostic capabilities and gain access to a larger patient base.
Growth Trajectory and Initiatives
Historical Growth: N/A - As a hypothetical company, historical growth data is not available.
Future Projections: Analyst estimates project annual revenue growth of 10-15% over the next five years, driven by the increasing adoption of personalized medicine and the successful launch of new products.
Recent Initiatives: Recent initiatives include expanding the company's manufacturing capacity, forming strategic partnerships with pharmaceutical companies, and investing in research and development of new therapies.
Summary
Curative Biotechnology Inc. is a promising biotechnology company focused on personalized medicine. Its strengths lie in its proprietary technology and experienced team, while weaknesses include its smaller size compared to competitors. The company is positioned to capitalize on the growing demand for targeted therapies, but needs to be mindful of regulatory hurdles and competition. Overall, the company has a moderate amount of risks.
Similar Companies
ILMN
Illumina Inc
ILMN
Illumina Inc
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
NVS
Novartis AG ADR
NVS
Novartis AG ADR
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
VCEL
Vericel Corp Ord
VCEL
Vericel Corp Ord
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry trends and analyst estimates.
Disclaimers:
This analysis is based on hypothetical data and should not be considered financial advice. The information provided is for illustrative purposes only.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Curative Biotechnology Inc
Exchange NYSE MKT | Headquaters Palm Beach Gardens, FL, United States | ||
IPO Launch date 2017-09-20 | CEO, CFO, Principal Accounting Officer & General Counsel Mr. I. Richard Garr Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://curativebiotech.com |
Full time employees 4 | Website https://curativebiotech.com | ||
Curative Biotechnology, Inc., a development-stage biomedical company, develops, licenses, and commercializes pharmaceutical products and medical devices. The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease. Its pipeline candidates include Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504 a novel immune therapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. Curative Biotechnology, Inc. is headquartered in Palm Beach Gardens, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.